get in touch if you don't see what you're looking for!
We're working on adding all of our packages. Stay tuned or Drug Repurposing Data Package
This package has 13 modules. The Clinical Trials Module has 16 tables. Preview the first five rows of each table or Explore the schema
Clinical Trials Module
16 Tables
Provides detailed information about clinical trials including interventions, trial arms, location, sponsor, trial conditions and more. Information is normalized, linked, and many relevant metadata descriptions are structured and ready for analysis.
id | trial_id | kind | label | description |
---|---|---|---|---|
000008b4-f6e0-4ff4-9483-3369f59f6a63 | NCT01232920 | active_comparator | Mycophenolate mofetil | |
00000ebb-1ffc-43df-a496-2da813782f88 | NCT06115408 | experimental | Drug;N-Acetylcysteine | 600 mg/day oral daily |
000016ed-4a6f-4cd8-add3-5a5e5eef7a82 | NCT01798745 | experimental | Cohort D: JNJ-54452840 for 5 days | Each patient will receive JNJ-54452840 once daily for 5 days at a dose determined by the Data Monitoring Committee (daily dose not exceeding 240 mg). |
000069a7-9ab3-427f-9735-00b0a4e2cfe8 | NCT05321706 | placebo_comparator | Placebo | Participants will be randomized in a 1:1 fashion to receive a matching tablet once daily for one year. |
00007875-d528-4445-b6b0-7601068667a7 | NCT05479812 | experimental | WTX-124 monotherapy dose expansion in advanced or metastatic RCC |
Want all 343,600 rows? Let's connect you to sales.
id | trial_id | title | condition_id |
---|---|---|---|
0 | NCT00000726 | Acquired Immunodeficiency Syndrome | 48294 |
1 | NCT00000726 | Communicable Diseases | 28178 |
2 | NCT00000726 | HIV Infections | 35016 |
3 | NCT00000726 | Immunologic Deficiency Syndromes | 28099 |
4 | NCT00000726 | Cytomegalovirus Retinitis | 283 |
Want all 339,236 rows? Let's connect you to sales.
id | trial_id | title | drug_id |
---|---|---|---|
0 | NCT00000726 | Foscarnet | 529 |
1 | NCT00000726 | Phosphonoacetic Acid | 2823 |
2 | NCT00000179 | Haloperidol decanoate | 502 |
3 | NCT00000179 | Trazodone | 656 |
4 | NCT00000179 | Haloperidol | 502 |
Want all 302,662 rows? Let's connect you to sales.
trial_id | condition_id |
---|---|
NCT06207370 | 21 |
NCT01306058 | 46 |
NCT00513604 | 48 |
NCT00924001 | 48 |
NCT00301509 | 61 |
Want all 312,268 rows? Let's connect you to sales.
trial_id | country |
---|---|
NCT00000102 | United States |
NCT00000105 | United States |
NCT00000116 | United States |
NCT00000117 | United States |
NCT00000119 | United States |
Want all 354,182 rows? Let's connect you to sales.
id | trial_id | sampling_method | gender | gender_based | gender_description | min_age | max_age | healthy_volunteers | criteria | population |
---|---|---|---|---|---|---|---|---|---|---|
00002007-b79a-468c-8976-5f7df5949f71 | NCT03246529 | All | 0 | 18 Years | 78 Years | No | Inclusion Criteria:
Histologically confirmed Multiple Myeloma prior to enrolment and randomization.
At least 1 week (7 days) from last induction cycle of combination/multi-agent cyto-reductive chemotherapy (e.g., KRD [carfilzomib, lenalidomide, dexamethasone] or VRD (e.g., bortezomib, lenalidomide, dexamethasone) or last single agent chemotherapy (e.g., lenalidomide, pomalidomide, bortezomib, dexamethasone, etc.) prior to the first dose of G-CSF for mobilization.
Eligible for autologous hematopoietic stem cell transplantation according to the Investigator's discretion.
The subjects should be in first or second CR (including CR and SCR) or PR (including PR and VGPR).
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Adequate organ function at screening as defined as below:
Hematology:
White blood cell counts more than 2.5 x 10^9/L
Absolute neutrophil count more than 1.5 x 10^9/L
Platelet count more than 100 x10^9/L Renal Function:
• Glomerular Filtration Rate (GFR) value of ≥15 mL/min/1.732 calculated by Modification of Diet in Renal Disease (MDRD) equation
Hepatic function:
Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤ 2.5 x ULN
Total Bilirubin ≤ 2.0 x Upper Limit Normal (ULN) unless the subject has Gilbert disease
Coagulation test:
International Normalized Ratio (INR) or Prothrombin Time (PT): ≤1.5 x ULN unless subject is receiving anticoagulant therapy, as long as PT or Partial Thromboplastin Time (PTT) is within therapeutic range of intended use of anticoagulants
Activated Partial Thromboplastin Time (aPTT): ≤1.5 x ULN unless subject is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants
Male subjects must agree to use an adequate method of contraception starting with the first day of G-CSF administration through 30 days after the last dose of study drug.
Patients must have a signed study informed consent prior to entering the study.
Exclusion Criteria:
Previous history of autologous or allogeneic-Hematopoietic Cell Transplantation (HCT).
Failed previous Hematopoietic Stem Cell (HSC) collections or collection attempts.
Taken any of the listed below concomitant medications, growth factors or stimulating agents within the designated washout period:
Dexamethasone: 7 days;
Thalidomide: 7 days;
Lenalidomide: 7 days;
Pomalidomide: 7 days;
Bortezomib: 7 days;
Carfilzomib: 7 days;
G-CSF: 14 days;
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) or Neulasta®: 21 days;
Erythropoietin or erythrocyte stimulating agents: 30 days;
Eltrombopag, romiplostim or platelet stimulating agents: 30 days;
Carmustine (BCNU): 42 days/6 weeks;
Daratumumab: 28 days;
Ixazomib: 7 days.
Received >6 cycles lifetime exposure to thalidomide or lenalidomide.
Received >8 cycles of alkylating agent combinations.
Received >6 cycles of melphalan.
Received prior treatment with radioimmunotherapy (e.g., radionuclides, holmium).
Received prior treatment with venetoclax.
Plans to receive maintenance treatment within 60 days post-engraftment (e.g., lenalidomide, bortezomib, pomalidomide, thalidomide, carfilzomib, etc.)
Has received a live vaccine within 30 days of the planned start of G-CSF administration. Seasonal flu vaccines that do not contain live virus are permitted.
Known active central nervous system (CNS) metastases or carcinomatous meningitis.
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to BL-8040, G-CSF, or other agents used in the study.
Has an active infection requiring systemic therapy or uncontrolled infection.
Has a known additional malignancy that is progressing or requires active treatment.
Has an underlying medical condition that would preclude study participation.
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
O2 saturation < 92% (on room air).
Personal history or family history of Long QT Syndrome or Torsade de Pointes.
History of unexplained syncope, syncope from an uncorrected cardiac etiology, or family history of sudden cardiac death.
Myocardial infarction, coronary artery bypass grafting (CABG), coronary or cerebral artery stenting and /or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months or greater than Angina Pectoris Class >2 or New York Heart Association (NYHA) Heart Failure >2.
ECG in screening showing QTcF > 470 msec, and/or PR > 280 msec,.
Mobitz II 2nd degree Atrioventricular (AV) Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block, unless the patient has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities.
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Is pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial, starting with the screening visit through 30 days after the last dose of study drug.
Has a known history of HIV (HIV 1/2 antibodies)
Has known active Hepatitis B (e.g., Hepatitis B Surface Antigen [HBsAg] reactive) or Hepatitis C (e.g., Hepatitis C Virus [HCV] RNA [qualitative] is detected).
Untreated or unsuccessfully treated Hepatitis B or C. | |||
00003d89-d1ea-432e-9863-5bcd91e204e4 | NCT01756560 | All | 0 | 18 Years | 75 Years | No | Inclusion Criteria:
- age 18-75, no contraindication to regional anesthesia
Exclusion Criteria:
- peripheral neuropathy | |||
00005b5c-7a71-4602-a7fa-89d453a5decd | NCT00193258 | All | 0 | 18 Years | No | Inclusion Criteria:
To be included in this study, you must meet the following criteria:
- Metastatic or unresectable clear cell renal carcinoma confirmed by biopsy
- Previous nephrectomy is required
- Maximum of 1 previous systemic regimen for metastatic disease.
- Able to perform activities of daily living with minimal assistance
- Measurable disease
- Adequate bone marrow, liver and kidney
- Written informed consent.
Exclusion Criteria:
- Age < 18 years
- Treatment with more than 1 previous systemic regimen
- History of heart attack within 6 months
- Clinically significant cardiovascular disease
- Moderate to severe vascular disease.
- Active brain metastases.
- History or evidence by physical examination of brain tumor
- Seizures not controlled with standard medical therapy
- history of stroke or other serious disorders of the nervous system
- Clinical history of coughing or vomiting blood within the past 3 months.
- PEG tubes or G tubes
- Chronic therapy with NSAIDS or other platelet inhibitors
- Proteinuria
- Nonhealing wound, ulcer, or long bone fracture
- Clinical evidence or history of a bleeding disorder
- Requiring full dose anticoagulation with coumadin
- Receiving chronic steroid therapy
- Significant medical conditions.
- Tumors other than clear cell
- History of stroke within 6 months.
- History of abdominal fistula,perforation,or abscess within 6 months.
Please note: There are additional inclusion/exclusion criteria. The study center will
determine if you meet all of the criteria. If you do not qualify for the trial, study
personnel will explain the reasons. If you do qualify, study personnel will explain the
trial in detail and answer any questions you may have. | ||||
0000a853-07b6-42bf-b37a-74ac0019e8d7 | NCT05443984 | All | 0 | 19 Years | No | - Inclusion Criteria: Subjects must satisfy all the following criteria.
1. Male or female, ≥ 19 years of age at the time of obtaining consent
2. Subjects who had experienced heartburn and regurgitation within 7 days prior to
the screening visit, those whose severity and frequency of symptoms fall under
the following (1) or (2)
⑴ Subjects who have experienced mild or more severe heartburn or regurgitation at
least twice a week
⑵ Subjects who have experienced moderate or more severe heartburn or
regurgitation at least once a week
3. Endoscopically confirmed grade A or higher erosive esophagitis as defined by
†LosAngeles classification within 15 days, prior to randomization
4. Subjects who fully understand this study and voluntarily signed on the informed
consent form
- Exclusion Criteria: Subjects may not satisfy any of the following criteria.
1. Subjects who can't undergo endoscopy
2. Medical History
º Subjects who have warning symptoms of the malignant gastrointestinal tract such
as odynophagia, severe dysphagia, bleeding, weight loss, anemia, or bloody stool.
(except negative result for malignancy by endoscopy)
º Subjects with eosinophilic esophagitis (except negative result by esophageal
biopsy)
º Subjects who have esophageal stenosis, gastroesophageal varices, Barrett's
esophagus, active gastric ulcer, gastrointestinal bleeding, or malignant tumor
confirmed by EGD
º Zollinger-Ellison syndrome patients
º Subjects diagnosed with primary esophageal motility disorder, irritable bowel
syndrome (IBS), inflammatory bowel disease (IBD), or suspected with IBS in the
last 3 months and with a current history of the disease including pancreatitis
º Subjects who have a history of gastric acid suppression surgery,
gastrointestinal or esophageal surgery (except appendectomy, cholecystectomy,
polypectomy)
º Subjects with a history of clinically significant hepatic, renal,
cardiovascular, respiratory, endocrine, urinary, neuro-psychiatric,
hemato-oncologic disorder
º Subjects who have a history of malignant tumor in 5 years at the time of
screening. However, excluding subjects with malignant gastrointestinal cancer
regardless of the period.
3. Laboratory Test
Screening laboratory test showing any of the following abnormal laboratory
results:
º ALT or AST > 2.0 x ULN
º ALP or GGT > 2.0 x ULN
º Total bilirubin > 2.0 x ULN
º eGFR<70 mL/min/1.73 m2 (CKD-EPI formula)
º Positive result for Serological test (HBsAg, HCV Ab, HIV Ab, Syphilis reagin
test)
º Clinically significant ECG abnormalities
4. Allergy and drug hypersensitivity
º Known hypersensitivity to the active ingredient or excipients of the
investigational product
º Clinically significant allergies (except mild allergic rhinitis) or
hypersensitivity history to drugs. (Aspirin, antibiotics, etc.)
5. Prohibited medication and therapy
º Subjects who take gastric acid suppressant like P-CAB, PPI within 2weeks prior
to EGD of screening procedure
º Subjects who take medication (antacids, prokinetics, H2RA, etc.) related to
reflux esophagitis more than 2times within 1week prior to EGD of screening
procedure
º Subjects who need to take medication (aspirin, NSAIDs, etc.) that may cause an
ulcer, during the study period
º Subjects who are on or need to be on the medications which categorized as
contraindicated in this clinical trial.
However, subjects who are on the contraindicated medications can participate in
the trial after the washout period of 2 weeks. If five times of the half-life of
the contraindicated medications exceeds 2 weeks, the washout period will be set
as five times of the half-life.
6. Pregnant and lactating women
7. Contraception Subjects who do not agree to use medically acceptable methods of
contraception during the period study
8. Subjects with clinically significant psychiatric disorder and a history with a
drug and alcohol abuse.
9. Subjects who are judged unsuitable to participate in the study in the opinion of
the investigator | ||||
00012e02-17e3-4bd5-95bc-ce17b49e8423 | NCT04163419 | All | 0 | 18 Years | No | Inclusion Criteria:
1. Patients must have a confirmed diagnosis schwannomatosis by fulfilling either clinical
or molecular diagnosis.
2. Age ≥ 18 years. Patients < 18 years are excluded since the safety profile of tanezumab
in this population has not been determined.
3. ECOG performance status ≤2 or Karnofsky ≥60%
4. Participants must have normal organ and marrow function as defined per the full
protocol
5. The subject's weight must be≥ 45 kg at Screening.
6. The subject must be willing to avoid prohibited pain medications (including
non-steroidal anti-inflammatory drugs) throughout the duration of the study except as
permitted per Protocol.
7. Subject must have moderate to severe pain secondary to schwannomatosis, defined as
Score ≥5 on the Numeric Rating Scale-11 (NRS-11) at Screening.
8. Subject must have failure, intolerance, or contraindication to at least three standard
of care therapies:
- Documented history indicating that NSAID therapy has not provided adequate pain
relief or subject is unable to take NSAIDs due to contraindication or inability
to tolerate.
- Documented history indicating that opioid treatment has not provided adequate
pain relief or subject is unwilling to take opioids, or unable to take opioids
due to contraindication or inability to tolerate
- Documented history indicating that neuropathic pain medications, such as
gabapentin, pregabalin, or others, have not provided adequate pain relief or
subject is unable to take these treatments due to contraindication or inability
to tolerate.
9. Female subjects of childbearing potential and at risk for pregnancy (e.g., not
abstinent) must agree to use 2 highly effective methods of contraception throughout
the study and for 112 days (16 weeks) after the last dose of assigned subcutaneous
study medication.
Exclusion Criteria:
1. Subjects with any of the following criteria: evidence of bilateral vestibular
schwannomas on imaging, a known germline pathogenic NF2 mutation, a first-degree
relative who meets diagnostic criteria for NF2, or have schwannomas limited to a
previous radiation field.
2. Subjects with intracranial meningioma associated with cerebral edema on neuroimaging.
Note: presence of intracranial meningioma itself is not an exclusion criterion.
3. Subjects who have had surgery, chemotherapy or radiotherapy within 4 weeks (6 weeks
for nitrosoureas or mitomycin C) for treatment of a painful schwannomatosis-related
tumor prior to entering the study or those who have not recovered from adverse events
due to agents administered more than 4 weeks earlier.
4. Participation in other studies involving investigational drug(s) (Phases 1-4) within
30 days (or 90 days for biologics) before Screening and/or during study participation.
5. Subjects receiving anticoagulation to treat an underlying medical condition.
6. Subject has a history of allergic or anaphylactic reaction to a therapeutic or
diagnostic monoclonal antibody or IgG fusion protein.
7. The subject's pain is related to a non-schwannomatosis cause such as prior cancer
therapy, infection, bowel obstruction/perforation, spinal cord compression, or
fracture or impending fracture of weight bearing bone.
8. The subject has a diagnosis of malignancy in the last 3 years (except for Gleason 6
prostate cancer, basal cell carcinoma or carcinoma in situ).
9. Use of concurrent adjuvant analgesics such as serotonin norepinephrine reuptake
inhibitors (SNRI), tricyclic antidepressants, anticonvulsant medication, or muscle
relaxants (unless the drugs were started at least 30 days prior to Screening and are
maintained at a stable dose).
10. Use of concurrent analgesic non-steroidal anti-inflammatory drugs (NSAIDs, including
selective COX-2 inhibitors) unless the subject is expected to be able to discontinue
these medications at least 2 weeks prior to treatment. Note: Subjects who take daily
low dose aspirin (≤ 325 mg as per local prescribing practice) therapy for
cardiovascular prophylaxis are not excluded from participation.
11. Diagnosis of osteoarthritis of the knee or hip as defined by the American College of
Rheumatology (ACR) combined clinical and radiographic criteria; Radiographic criteria
will be assessed by the Central Reader.
12. Use of concurrent corticosteroids (except for inhaled or topical corticosteroids as
needed for management of ongoing pulmonary or dermatologic conditions)
13. Subjects considered unfit for surgery, defined as Grade >3 on the American Society of
Anesthesiologists (ASA) physical classification system for surgery or subjects who
would not be willing to undergo joint replacement surgery if required.
14. Subjects with symptoms and radiographic findings (i.e. joint space narrowing,
osteophytes) consistent with osteoarthritis in the shoulder.
15. History of significant trauma or surgery to a major joint (e.g. hip, knee or shoulder)
within one year prior to Screening.
16. A history of osteonecrosis or osteoporotic fracture (i.e., a subject with a history of
osteoporosis and a minimally traumatic or atraumatic fracture).
17. Radiographic (x-ray) evidence of any of the following conditions as determined by the
central radiology reviewer at Screening: 1) rapidly progressive osteoarthritis, 2)
atrophic or hypotrophic osteoarthritis, 3) subchondral insufficiency fracture, 4)
spontaneous osteonecrosis of the knee (SPONK), 5) osteonecrosis, or 6) pathologic
fracture.
18. Subjects who have evidence of orthostatic hypotension based upon replicate orthostatic
blood pressure measurements at Screening.
19. Subjects with a total impact score of >7 on the Survey of Autonomic Symptoms (SAS) at
Screening.
20. Diagnosis of a transient ischemic attack in the 6 months prior to Screening or
diagnosis of stroke with residual deficits (e.g., aphasia, substantial motor or
sensory deficits), that would preclude completion of required study activities.
21. History, diagnosis, or signs and symptoms of clinically significant neurological
22. Subjects with a past history of carpal tunnel syndrome (CTS) with signs or symptoms of
CTS in the one year prior to Screening.
23. Subject with a history of significant alcohol, analgesic, or narcotic substance abuse
within the six months prior to Screening.
24. Subject who, in the judgement of the investigator, is expected to require a surgical
procedure during the duration of the study.
25. Previous exposure to exogenous nerve growth factor or to an anti-nerve growth factor
antibody.
26. Subjects who are investigational site staff members directly involved in the conduct
of the trial and their family members, site staff members otherwise supervised by the
Investigator, or subjects who are Pfizer employees directly involved in the conduct of
the trial
27. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.
28. Pregnant females; breastfeeding females; females of childbearing potential not using
two (2) methods of highly effective contraception or not agreeing to continue two (2)
methods of highly effective contraception for 112 days (16 weeks) after last dose of
investigational product.
29. Any subject who, in the judgement of the investigator, is deemed inappropriate for
participation in the study. |
Want all 182,587 rows? Let's connect you to sales.
id | trial_id | identifier | kind |
---|---|---|---|
0 | NCT00000726 | NCT00000726 | primary |
1 | NCT00000726 | ACTG 015 | org_study_id |
2 | NCT00000726 | FDA 20D | external |
3 | NCT00000726 | 10991 | external |
4 | NCT00001302 | NCT00001302 | primary |
Want all 458,858 rows? Let's connect you to sales.
intervention_id | arm_group_id |
---|---|
0000418e-26ed-4068-8765-000622067c44 | ebdf1308-3376-4ac3-ad4f-d4b5d45a8eeb |
00004645-6318-4239-86ca-127207ead9cb | 948fdf02-c4e2-45ee-b075-dc98018cb8b1 |
00006a6b-958b-438f-be34-fae8b88fafda | ec404ccd-ff78-4eb7-b003-3798cf295d68 |
00007b19-8b85-422b-81cb-496b74cf195c | 634e2d1f-1c0c-448c-93c2-b449b176a0cf |
00010094-d30b-4ca9-a327-a02bcd3a085f | 09d6f513-271a-4478-8966-3622eeb7e4ad |
Want all 517,712 rows? Let's connect you to sales.
id | trial_id | kind | title | description |
---|---|---|---|---|
0000418e-26ed-4068-8765-000622067c44 | NCT04982380 | drug | Siliankang simulating tablets | Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Siliankang simulative tablets 3 tablets p.o. tid for 12 weeks. |
00004645-6318-4239-86ca-127207ead9cb | NCT01097486 | procedure | Allograft | Single Dose Allograft Surgical Implantation |
00006a6b-958b-438f-be34-fae8b88fafda | NCT06338826 | drug | TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI | The study will include patients under current daily antiretroviral tritherapy not modified for ≥ 12 months must including tenofovir disoproxil fumarate (TDF) 245mg or tenofovir alafenamide fumarate (TAF -25mg) associated to lamivudine (3TC - 300mg) or emtricitabine (FTC - 200mg) and a NNRTI or PI/r or INSTI to choose from
NNRTI = efavirenz, rilpivirine, etravirine, doravirine
PI/r = atazanavir/r ou darunavir/r
INSTI = bictegravir, dolutegravir, elvitegravir/cobicistat, raltegravir |
00007b19-8b85-422b-81cb-496b74cf195c | NCT04721054 | drug | Thoracic epidural effect on heart rate in Laparoscopic Cholecystectomy (bupivacaine and lignocaine) | patients in epidural anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure |
00010094-d30b-4ca9-a327-a02bcd3a085f | NCT01171209 | drug | Interferon-beta and human leukocyte Interferon-α | One single injection of interferon(IFN)- β and one single injection of human leukocyte IFN-α (Multiferon® ) 6 MIU s.c. with 1-7 days follow-up. |
Want all 417,437 rows? Let's connect you to sales.
id | intervention_id | drug_id |
---|---|---|
302718 | 00007b19-8b85-422b-81cb-496b74cf195c | 281 |
302719 | 00007b19-8b85-422b-81cb-496b74cf195c | 297 |
108423 | 00010094-d30b-4ca9-a327-a02bcd3a085f | 60 |
108421 | 00010094-d30b-4ca9-a327-a02bcd3a085f | 5259 |
108422 | 00010094-d30b-4ca9-a327-a02bcd3a085f | 15697 |
Want all 369,699 rows? Let's connect you to sales.
id | intervention_id | name |
---|---|---|
0 | 72bf20ce-9e35-452a-9fb0-5278e331ffc4 | elavil plus prozac |
1 | a09d3d37-3a38-4798-bade-ac1c9d4383eb | Elavil |
2 | 88525cb1-9c27-4be5-a4c4-0057fecbb8c8 | Subutex |
3 | 88525cb1-9c27-4be5-a4c4-0057fecbb8c8 | Suboxone |
4 | f354cce2-1963-4e14-95d9-a3c8aa29ff15 | Revia |
Want all 336,720 rows? Let's connect you to sales.
id | intervention_id | product_id |
---|---|---|
67774 | 00010094-d30b-4ca9-a327-a02bcd3a085f | 89915 |
35970 | 0001d1b8-7d36-404f-8c5b-6c05e0b42053 | 394020 |
129886 | 00026781-4108-43e2-809c-1f6d9ab2f453 | 92016 |
57636 | 000326cf-dc94-4ea7-9579-01e3662cd783 | 310402 |
173139 | 00045bc5-f0d5-47eb-bae7-e6fdb08d7102 | 531383 |
Want all 174,433 rows? Let's connect you to sales.
trial_id | phase |
---|---|
NCT00017381 | 0 |
NCT00091286 | 0 |
NCT00140556 | 0 |
NCT00176059 | 0 |
NCT00187941 | 0 |
Want all 165,004 rows? Let's connect you to sales.
id | trial_id | title | agency_class | lead_sponsor |
---|---|---|---|---|
0 | NCT00000726 | National Institute of Allergy and Infectious Diseases (NIAID) | nih | 1 |
1 | NCT00001302 | National Cancer Institute (NCI) | nih | 1 |
2 | NCT00000179 | National Institute on Aging (NIA) | nih | 1 |
3 | NCT00000333 | National Institute on Drug Abuse (NIDA) | nih | 1 |
4 | NCT00000333 | Washington D.C. Veterans Affairs Medical Center | us_fed | 0 |
Want all 281,181 rows? Let's connect you to sales.
identifier | title | official_title | status | purpose | expanded_access | why_stopped | why_stopped_category_id | start_date | end_date | end_date_kind |
---|---|---|---|---|---|---|---|---|---|---|
NCT00000102 | Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets | completed | treatment | 1 | ||||||
NCT00000105 | Vaccination With Tetanus and KLH to Assess Immune Responses. | Vaccination With Tetanus Toxoid and Keyhole Limpet Hemocyanin (KLH) to Assess Antigen-Specific Immune Responses | terminated | 1 | Replaced by another study. | 136 | 2002-07-01 | 2012-03-01 | actual | |
NCT00000114 | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa | completed | treatment | 1 | 1984-05-01 | 1987-06-01 | actual | |||
NCT00000115 | Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema | completed | treatment | 1 | 1990-12-01 | 1994-06-01 | actual | |||
NCT00000116 | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A | Clinical Trial of Docosahexaenoic Acid (DHA) in Patients With Retinitis Pigmentosa Receiving Vitamin A Treatment | completed | treatment | 1 | 1996-05-01 | 2002-09-01 | actual |
Want all 182,950 rows? Let's connect you to sales.
id | category | definition | safety_efficacy_concern |
---|---|---|---|
1 | Business Decision | The trial has been terminated due to strategic decisions, administrative reasons, sponsor, or company decision. | 0 |
6 | Change in Medical/Clinical Practices | The drug(s) of interest might not be suitable to the disease that they were trying to treat due to changes in medical or clinical practices.
1. Surgeons stopped doing procedures
2. Additional published information on the topic since starting the study
3. Study no longer consistent with current clinical practice
| 0 |
11 | Competing Studies | The study drug(s) are having worse/futile results in similar competing trials. | 0 |
16 | Completed | Trial was successfully completed (user input was incorrectly marked as terminated). [eg. accrual was reached] | 0 |
21 | Conflict of Interest | The parties involved had conflicts of interests. | 0 |
Want all 30 rows? Let's connect you to sales.
Showing 16 of 16 tables